Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01616667
Other study ID # S-20120009
Secondary ID A2116 Signe Rose
Status Completed
Phase Phase 2
First received May 30, 2012
Last updated June 3, 2015
Start date May 2012
Est. completion date May 2015

Study information

Verified date June 2015
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection AgencyDenmark:The Regional Committee on Biomedical Research Ethic
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the clinical outcome of the two different, but widely used, surgical approaches (Posterior approach and Lateral approach) of primary total hip arthroplasty in patients diagnosed with osteoarthritis. This study is divided into one main study and two sub-studies. The main study investigates the patient-reported outcome measures (questionnaire) within the first year post surgery. The two sub-studies investigate; i) the level of physical function and pain within the first 3 month after surgery, and ii) investigate the potential difference the two approaches have on gait-patterns and maximal isometric hip-muscle-strength, within the first year after surgery. Both approaches are described with potential drawbacks. Posterior approach has a higher risk of dislocation of the prostheses and revision due to dislocation compared with Lateral approach. Contrary, Lateral approach is described with the potential drawbacks of pain, lower physical function, gait abnormalities and muscle weakness, leading to less satisfied patients. However, according to a Cochrane analysis from 2004 concludes, more investigation is needed to determine the extent of differences.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 45 Years to 70 Years
Eligibility Inclusion Criteria:

- Age: 45-70 years, both included.

- Patients schedule for primary cementless total hip arthroplasty.

- Endstage hip osteoarthritis(OA) or minor dysplasia of the hip(CE-angle > 20 degrees).

Exclusion Criteria:

1. more major joint (hip or knee) than the current hip affected with OA, with expected joint replacement surgery within a year.

2. Prior joint replacement surgery on any major joint (hip, knee) in lower limb.

3. BMI above 35.

4. Any physical disability that prevents patients from walking 20 meters without aid.

5. The patients is not suitable for standard cementless prosthetic components.

6. Any neurological disease (ex. cerebral thrombosis, Parkinson) compromising the walking ability.

7. Any severe medical condition compromising walking ability (ex. chronic heart failure, chronic obstructive pulmonary disease).

8. Severe dementia.

9. Inability to read and understand Danish writing and oral instructions.

10. Do not want to participate

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Total hip arthroplasty
The patients included is operated with a total hip arthroplasty due to primary osteoarthritis

Locations

Country Name City State
Denmark Odense University Hospital Odense

Sponsors (8)

Lead Sponsor Collaborator
Odense University Hospital Bevica Fonden, Bjarne Jensens Fond, Orthopaedic department of Køge Hospital, Region of Southern Denmark, Region Zealand, The Danish Rheumatism Association, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hip Disability and Osteoarthritis Outcome Score (HOOS)-Physical Function Short form(HOOS-PS), 12 month Primary study:
Hip Disability and Osteoarthritis Outcome Score (HOOS) includes five subscales: 1)Pain 2) Other symptoms 3) Activities of daily living(ADL) 4) Sport and recreation function and 5) Hip related quality of life. HOOS-Physical Function Short form (HOOS-PS) is an aggregation and shortening of the two original subscales of HOOS-ADL and Sport and Recreation. HOOS-PS is a validated instrument. HOOS has been translated to Danish.
We will use HOOS-PS as primary outcome.
Endpoint 12 month No
Secondary Hip Disability and Osteoarthritis Outcome Score (HOOS)-pain, 12 month Primary study Baseline, 3 month, 6 month and endpoint 12 month No
Secondary Hip Disability and Osteoarthritis Outcome Score (HOOS)-Hip related quality of life, 12 month Primary study Baseline, 3 month, 6 month and endpoint 12 month No
Secondary University of California Los Angeles activity score (UCLA), 12 month Primary study:
University of California Los Angeles activity score (UCLA) is a score focusing on patient activity level. The score is based on a scale from 1 to 10, ranging from inactive to regularly participate in impact sport or heavy labor. UCLA contributes with important qualitative information with regard to patient activity in correlation with other clinical outcome measures. UCLA is found reliable and valid and is translated to Danish.
Baseline, 3 month, 6 month and endpoint 12 month No
Secondary EQ-5D self-rated health index -and EQ VAS scores, 12 month Primary study:
EuroQol/EQ-5D is a standardized, reliable and validated instrument to measure quality of life. The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, and the EQ VAS that records the respondent's overall self-rated health on a vertical, visual analogue scale. EQ-5D is translated to Danish.
Baseline, 3 month, 6 month and endpoint 12 month No
Secondary The 20 meter walk-test (20MeWa) Sub-study 1:
The 20 meter walk-test (20MeWa). Patients are instructed to walk 20 meters between two clearly visible lines marked on the floor. The patients are instructed to walk with their usual pace on two trials and on the two following trials to walk at maximal pace, at which they feel secure. The mean velocity of each two trials are used for further analysis.
Baseline, 3 days, 21 days and endpoint 3 month No
Secondary "Timed Up and Go"- test (TUG), 3 month Sub-study 1:
The "Timed Up and Go" test (TUG) measures the time it takes a person to rise from a chair walk 3 meters, turn and walk back to the chair and sit down again. TUG is found to be a reliable and valid test for quantifying functional mobility.
Baseline, 3 days, 21 days and endpoint 3 month No
Secondary "Repeated chair rise"- test (RCR), 3 month Sub-study 1:
"Repeated chair rise"- test (RCR) assess the strength of the lower limb muscles overall. The test measures the maximum "stand and sit" cycles the test-person can perform on a chair within in 30 seconds. The test has been showed to gives a reliable and valid measurement of lower body strength in generally active older adults.
Baseline, 3 days, 21 days and endpoint 3 month No
Secondary 30 seconds maximal repeated unilateral knee bending, 3 month Sub-study 1:
30 seconds maximal repeated unilateral knee bending. It evaluates the maximum number of knee bends performed on one leg in 30 seconds and the ability to execute fast coupled eccentric-concentric muscle force over the knee joint. The patient stand aligned with the front of their foot touching a straight line taped to the floor; finger tip support for balance is provided by the examiner. The patient is then asked to bend the knee, without bending forward from the hip, until he/she could no longer see the line at the toes (about 30ยบ of knee flexion).
Baseline, 3 days, 21 days and endpoint 3 month No
Secondary Opioid consumption, 3 month Sub-study 1:
The opioid consumption will be patient administrated and recorded each day, the first 5 days after surgery. After discharged the patient will fill in a patients-diary, where the analgesics consumption are registered.
Baseline, 1,2,3,4,5 days, 2, 3, 4, 6,8,10 weeks and endpoint 12 week No
Secondary Self-reported pain on a numerical ranking scale(NRS), 3 month Sub-study 1:
The self-reported pain on a numerical ranking scale(NRS)will be recorded each day, the first 5 days after surgery. After discharged the patient will fill in a patients-diary, where the NRS are registered.
Baseline, 1,2,3,4,5 days, 2, 3, 4, 6,8,10 weeks and endpoint 12 week No
Secondary Hip Disability and Osteoarthritis Outcome Score (HOOS)-pain, 3 month Sub-study 1:
We will use the Hip Disability and Osteoarthritis Outcome Score (HOOS)subscales -Pain.
It will be recorded after discharged in a patients-diary
Baseline, 5 days, 2, 3, 4, 6,8,10 weeks and endpoint 12 week No
Secondary Hip Range of motion (ROM), 3 month Sub-study 1:
Range of motion in the hip joint evaluated by goniometer at baseline and 3 month post-surgery Extension/Flexion. Abduction/adduction. Internal/external rotation.
Baseline and endpoint 3 month No
Secondary Gait Deviation Index(GDI), 12 month Sub-study 2:
Data from 3 dimensional gait analysis(6 camara Vicon MX Motion Analysis system), including EMG analysis during gait.
Gait Deviation Index (GDI) was created to present gaitanalysis data in one score to give a comprehensive evaluation of the patients ambulation compared to healthy subjects. GDI is calculated from 15 kinematic variables, representing 98% of the variation in gait-patterns. A GDI score upon 100 represent normal gait. Every 10 points below this represent 1 standard deviation (SD) from normal gait.
Baseline, 3 month, and endpoint 12 month No
Secondary Kinematic gait data, 12 month Sub-study 2:
Data from 3 dimensional gait analysis(6 camara Vicon MX Motion Analysis system), including EMG analysis during gait.
Kinematic:
Sagittal hip Range of motion: extension/flexion. Frontal hip Range of motion: abduction/adduction. Frontal trunk inclination: left and right movement of the trunk.
Baseline, 3 month, and endpoint 12 month No
Secondary Temporospatial parameters, 12 month Sub-study 2:
Data from 3 dimensional gait analysis(6 camara Vicon MX Motion Analysis system), including EMG analysis during gait.
Temporospatial parameters:
Velocity. Cadance. Step duration. Stance duration
Baseline, 3 month, and endpoint 12 month No
Secondary Electromyography (EMG) during walk, 12 month Sub-study 2:
Data from 3 dimensional gait analysis(6 camara Vicon MX Motion Analysis system), including EMG analysis during gait.
Electromyography (EMG)during walk:
Peak EMG- in stance phase (absolute/normalized to MVC) Mean EMG- in stance phase (absolute/normalized to MVC) Integrated EMG during stancephase
Baseline, 3 month, and endpoint 12 month No
Secondary Isometric maximal voluntary muscle contraction(MVC), 12 month Sub-study 2:
Data from: Isometric maximal voluntary muscle contraction(MVC), including EMG analysis during test.
Maximal force (Fmax):
Hip Extension Flexion and Abduction. Rate of force development(RFD): Hip Extension. Flexion and Abduction
Baseline, 3 month, and endpoint 12 month No
Secondary Limping question from Harris Hip Score Primary study Baseline, 3 month, 6 month and endpoint 12 month No